Risk factors for failure of Helicobacter pylori therapy -: results of an individual data analysis of 2751 patients

被引:170
作者
Broutet, N
Tchamgoué, S
Pereira, E
Lamouliatte, H
Salamon, R
Mégraud, F
机构
[1] Univ Bordeaux 2, Bacteriol Lab, Unite Epidemiol Malad Digest, F-33076 Bordeaux, France
[2] Hop St Andre, Serv Gastroenterol, Bordeaux, France
[3] Univ Bordeaux 2, INSERM, U330, Inst Sante Publ Dev, F-33076 Bordeaux, France
关键词
D O I
10.1046/j.1365-2036.2003.01396.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aim: To study risk factors for failure of Helicobacter pylori eradication treatment. Methods: Individual data from 2751 patients included in 11 multicentre clinical trials carried out in France and using a triple therapy, were gathered in a unique database. The 27 treatment regimens were regrouped into four categories. Results: The global failure rate was 25.8%[95% CI: 24-27]. There was a difference in failure rate between duodenal ulcer patients and non-ulcer dyspeptic patients, 21.9% and 33.7%, respectively (P < 10(-6) ). In a random-effect model, the risk factors identified for eradication failure in duodenal ulcer patients (n = 1400) were: to be a smoker, and to have received the group 4 treatment, while to receive a 10 day treatment vs. 7 days protected from failure. In non-ulcer dyspeptic patients (n = 913), the group 2 treatment was associated with failure. In both groups, age over 60 was associated with successful H. pylori eradication. There were less strains resistant to clarithromycin in duodenal ulcer patients than in non-ulcer dyspeptic patients. Clarithromycin resistance predicted failure almost perfectly. Conclusion: Duodenal ulcer and non-ulcer dyspeptic patients should be managed differently in medical practice and considered independently in eradication trials.
引用
收藏
页码:99 / 109
页数:11
相关论文
共 38 条
[31]  
2-#
[32]   Diversity of Helicobacter pylori vacA and cagA genes and relationship to VacA and CagA protein expression, cytotoxin production, and associated diseases [J].
Rudi, J ;
Kolb, C ;
Maiwald, M ;
Kuck, D ;
Sieg, A ;
Galle, PR ;
Stremmel, W .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (04) :944-948
[33]  
*STAT CORP, 2001, STAT GRAPH DAT MAN
[34]   One-week ranitidine bismuth citrate in combinations with metronidazole, amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection:: the RBC-MACH study [J].
Sung, JJY ;
Chan, FKL ;
Wu, JCY ;
Leung, WK ;
Suen, R ;
Ling, TKW ;
Lee, YT ;
Cheng, AFB ;
Chung, SCS .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1999, 13 (08) :1079-1084
[35]   Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia [J].
Talley, NJ ;
Vakil, N ;
Ballard, ED ;
Fennerty, MB .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (15) :1106-1111
[36]   Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment [J].
van Doorn, LJ ;
Schneeberger, PM ;
Nouhan, N ;
Plaisier, AP ;
Quint, WGV ;
de Boer, WA .
GUT, 2000, 46 (03) :321-326
[37]   Treatment of Helicobacter pylori infection with low or high dose omeprazole combined with amoxycillin and the effect of early retreatment [J].
vanderHulst, RWM ;
Weel, JFL ;
Verheul, SB ;
Keller, JJ ;
tenKate, FJW ;
van der Ende, A ;
Rauws, EAJ ;
Dankert, J ;
Tytgat, GNJ .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1996, 10 (02) :165-171
[38]  
1996, GASTROENTEROL CLIN B, V20, pS1